December 9, 2019
AB Science announces publication of three AB8939 scientific abstracts in the special ASH Annual Meeting issue of Blood
AB Science SA (NYSE Euronext - FR0010557264 - AB) today announced that three scientific abstracts regarding its AB8939 preclinical development program were published in the ...
December 9, 2019
Actinium Pharmaceuticals Highlights 86% Response Rate and 71% MRD Negative Rate in Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML at ASH 2019 Annual Meeting
NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") today highlighted new data from a Phase 1 trial studying Actimab-A in ...
December 9, 2019
Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex
RADNOR, Pa., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics ...
December 9, 2019
Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of Hematology
SAN DIEGO, CA and CALGARY, AB / ACCESSWIRE / December 9, 2019 / Oncolytics Biotech® Inc. (ONCY)(ONC.TO), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, ...
December 9, 2019
Kamada Enters into a Binding Term Sheet for Contract Manufacturing of an FDA Approved, Commercialized Hyper-Immune Globulin Product
REHOVOT, Israel, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (Nasdaq: KMDA; TASE: KMDA.TA), a plasma-derived protein therapeutics company, today announced that it has entered ...
December 9, 2019
Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency
NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell ...
December 9, 2019
Vaccinex Details Scientific Rationale for Expanding Pepinemab Clinical Programs to Include Alzheimer’s Disease
ROCHESTER, N.Y., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and nuerodegenerative diseases, ...
December 9, 2019
Catalyst Biosciences Presents Two Posters on MarzAA at the 61st Annual American Society of Hematology Conference
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other ...
December 9, 2019
Spring Bank to Present Data on its Novel Chimeric Antisense Oligonucleotide Compounds for Hepatitis B at HepDART 2019
HOPKINTON, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
December 9, 2019
Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference
FLORHAM PARK, N.J., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs ...
December 9, 2019
Abeona Therapeutics Cleared to Initiate Pivotal Phase 3 Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
NEW YORK and CLEVELAND, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (ABEO), a fully-integrated leader in gene and cell therapy, today announced that ...
December 9, 2019
Molecular Templates Announces Presentations at the American Society of Hematology (ASH) 2019 Annual Meeting
AUSTIN, Texas, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (MTEM) a clinical-stage biopharmaceutical  company focused on the discovery and development of the Company’s ...
December 9, 2019
Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting
SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics ...
December 9, 2019
Valneva Appoints Renowned Vaccinologists Stanley Plotkin and Anna Durbin to its Scientific Advisory Board
Saint-Herblain (France), December 9, 2019 – Valneva SE (“Valneva” or “the Company”) today announced the appointment of two leading vaccine experts to its Scientific Advisory ...
December 9, 2019
Onxeo Announces its Financial Agenda for 2020
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA ...
December 9, 2019
Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data
Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central ...
December 9, 2019
Transgene Announces Investor Meetings for January 2020
Transgene (Paris:TNG) today announces that Management will participate in the upcoming investor events set out below. Transgene will meet institutional investors at the LifeSci Advisors ...
December 9, 2019
Quantum Genomics and Biolab Sanus Pharmaceutical Enter into Exclusive Licensing and Collaboration Agreement for Firibastat in Latin America
PARIS and NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug ...
December 3, 2019
Axovant Announces Amendment to Credit Facility with Hercules Capital
Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced the completion of an amendment to its loan and security agreement ...
December 3, 2019
Genkyotex Reports Progress of Setanaxib Phase 2 Investigator Initiated Trials
ARCHAMPS, France, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) a biopharmaceutical company and the leader in NOX therapies, ...
Page 110 of 176